Should I discontinue eplerenone in a patient with acute kidney injury, serum creatinine 2.5 mg/dL and estimated glomerular filtration rate < 30 mL/min/1.73 m², due to risk of hyperkalemia?

Discontinuation of Eplerenone in Acute Kidney Injury with Severe Renal Dysfunction

Yes, you must discontinue eplerenone immediately in this patient with serum creatinine 2.5 mg/dL and eGFR <30 mL/min/1.73 m², as this represents a Class III (Harm) contraindication according to ACC/AHA guidelines and FDA labeling. 1, 2

Guideline-Based Contraindications

The use of aldosterone receptor antagonists is potentially harmful and contraindicated when: 1

• Serum creatinine >2.5 mg/dL in men (or >2.0 mg/dL in women)
• eGFR <30 mL/min/1.73 m²
• Potassium >5.0 mEq/L

The FDA drug label explicitly states eplerenone is contraindicated in all patients with creatinine clearance ≤30 mL/min. 2 Your patient meets both the creatinine and eGFR thresholds for immediate discontinuation.

Rationale for Discontinuation

Life-Threatening Hyperkalemia Risk

The risk of hyperkalemia increases dramatically with declining renal function. In patients with baseline creatinine clearance ≤30 mL/min, hyperkalemia (>5.5 mEq/L) occurred in 32% of eplerenone-treated patients versus 23% with placebo in the EPHESUS trial. 2 The European Society of Cardiology guidelines emphasize that significant renal dysfunction (creatinine >221 μmol/L [>2.5 mg/dL] or eGFR <30 mL/min/1.73 m²) requires seeking specialist advice and represents a major caution for mineralocorticoid receptor antagonist use. 1

Acute Kidney Injury Context

In the setting of acute kidney injury, the risk-benefit ratio becomes even more unfavorable: 3

• Eplerenone causes modest but persistent reductions in eGFR
• WRF (worsening renal function) and hyperkalemia are interrelated complications
• Patients with baseline renal impairment are at highest risk

Discontinuation Protocol

Immediate Actions

1. Stop eplerenone immediately without tapering (no formal taper is required for mineralocorticoid receptor antagonists, unlike beta-blockers). 4

2. Check potassium and creatinine within 1 week after discontinuation to confirm resolution of any hyperkalemia or further renal deterioration. 4

3. Discontinue any potassium supplements if the patient is receiving them. 1

4. Review concomitant medications that may be contributing to renal dysfunction (NSAIDs, other nephrotoxic agents). 1

Post-Discontinuation Monitoring

• Recheck serum potassium and creatinine within 1 week to document improvement. 4
• Monitor for resolution of acute kidney injury over the following 1-2 weeks. 4
• In heart failure patients, watch for signs of volume overload or worsening symptoms after discontinuation. 4

Alternative Heart Failure Management Strategies

If this patient has heart failure and eplerenone was being used for prognostic benefit, optimize alternative therapies: 4

• Maximize beta-blocker therapy if tolerated (even low doses provide mortality benefit)
• Ensure adequate ACE inhibitor or ARB therapy (though these also require careful monitoring at this renal function level)
• Consider hydralazine-nitrate combination (demonstrated mortality benefit in heart failure patients not on neurohormonal antagonists)
• Optimize diuretic therapy to manage volume status

Critical Considerations for Reinitiation

Do not restart eplerenone until: 1

• Acute kidney injury has completely resolved
• Serum creatinine returns to <2.5 mg/dL
• eGFR improves to >30 mL/min/1.73 m²
• Potassium is <5.0 mEq/L

Even if renal function improves, eplerenone should only be restarted at a reduced dose (25 mg every other day) if eGFR remains 30-49 mL/min/1.73 m², with intensive monitoring at 3 days, 1 week, then monthly for 3 months. 1

Common Pitfalls to Avoid

• Do not attempt dose reduction instead of discontinuation when creatinine is >2.5 mg/dL or eGFR <30 mL/min/1.73 m². The guidelines specify complete discontinuation at these thresholds. 1

• Do not wait for potassium to rise before discontinuing. The renal dysfunction alone is sufficient indication for immediate cessation. 1, 2

• Do not combine triple RAAS blockade (ACE inhibitor + ARB + aldosterone antagonist) if considering future reinitiation, as this dramatically increases hyperkalemia risk. 1

• Remember that serum creatinine underestimates renal dysfunction in elderly patients or those with low muscle mass—always calculate eGFR. 1